Phreesia
0
Funds holding %
of 7,398 funds
0
Analysts bullish %
of 6 analysts
Fund manager confidence
Based on 2024 Q4 regulatory filings by fund managers ($100M+ AUM)
30% more call options, than puts
Call options by funds: $10.9M | Put options by funds: $8.4M
10% more capital invested
Capital invested by funds: $1.25B [Q3] → $1.38B (+$124M) [Q4]
8% more repeat investments, than reductions
Existing positions increased: 68 | Existing positions reduced: 63
8% more first-time investments, than exits
New positions opened: 28 | Existing positions closed: 26
1% less funds holding
Funds holding: 190 [Q3] → 188 (-2) [Q4]
1.2% less ownership
Funds ownership: 95.46% [Q3] → 94.25% (-1.2%) [Q4]
Research analyst outlook
6 Wall Street Analysts provided 1 year price targets over the past 3 months
Low target
$29
11%
upside
Avg. target
$32
24%
upside
High target
$35
34%
upside
6 analyst ratings
6 positive
100%
0 neutral
0%
0 negative
0%
Canaccord Genuity Richard Close 41% 1-year accuracy 11 / 27 met price target | 34%upside $35 | Buy Maintained | 13 Mar 2025 |
Needham Ryan MacDonald 36% 1-year accuracy 30 / 84 met price target | 11%upside $29 | Buy Reiterated | 13 Mar 2025 |
Piper Sandler Jessica Tassan 38% 1-year accuracy 9 / 24 met price target | 26%upside $33 | Overweight Reiterated | 29 Jan 2025 |
Citigroup Daniel Grosslight 39% 1-year accuracy 9 / 23 met price target | 34%upside $35 | Buy Maintained | 10 Jan 2025 |
Keybanc Scott Schoenhaus 17% 1-year accuracy 2 / 12 met price target | 15%upside $30 | Overweight Maintained | 8 Jan 2025 |
Financial journalist opinion
Based on 5 articles about PHR published over the past 30 days
Positive
Seeking Alpha
2 weeks ago
Phreesia Maintains Its Momentum
Phreesia remains resilient, maintaining guidance and showing strong financial performance, with Q4 revenue growth of 15% year-over-year and improved cash flow. Despite a slight deceleration in customer growth, Phreesia's revenue per healthcare services client increased, driven by network solutions, and the company expects 13.6% revenue growth in fiscal 2026. Future growth drivers include patient education initiatives and Post-Script Engagement, while competition is seen as beneficial, enhancing market awareness and adoption of healthcare solutions.

Neutral
Business Wire
2 weeks ago
Phreesia Named to G2's List of 2025 Best Healthcare Software Products
ALL-REMOTE COMPANY/WILMINGTON, Del.--(BUSINESS WIRE)--Phreesia has been named to G2's 2025 Best Software Awards in the Best Healthcare Software Products category.

Neutral
Seeking Alpha
2 weeks ago
Phreesia, Inc. (PHR) Q4 2025 Earnings Call Transcript
Phreesia, Inc. (NYSE:PHR ) Q4 2025 Earnings Conference Call March 12, 2025 5:00 PM ET Company Participants Balaji Gandhi - CFO Chaim Indig - Co-Founder, CEO & Director Conference Call Participants Anne Samuel - JPMorgan Jessica Tassan - Piper Sandler Jailendra Singh - Triust Securities Ryan Daniels - William Blair Richard Close - Canaccord Genuity Ryan MacDonald - Needham & Company Jeff Garro - Stephens Daniel Grosslight - Citi Group Scott Schoenhaus - KeyBanc Capital Markets Operator Good evening, ladies and gentlemen, and welcome to Phreesia's Fourth Quarter Fiscal 2025 Earnings Conference Call. [Operator Instructions] First, I would like to introduce Balaji Gandhi, Phreesia's Chief Financial Officer.

Negative
Zacks Investment Research
2 weeks ago
Phreesia (PHR) Reports Q4 Loss, Tops Revenue Estimates
Phreesia (PHR) came out with a quarterly loss of $0.11 per share versus the Zacks Consensus Estimate of a loss of $0.19. This compares to loss of $0.56 per share a year ago.

Neutral
Business Wire
3 weeks ago
Phreesia Announces Fourth Quarter Fiscal 2025 Results
ALL-REMOTE COMPANY/WILMINGTON, Del.--(BUSINESS WIRE)--Phreesia, Inc. (NYSE: PHR) (“Phreesia” or the "Company") announced financial results today for the fiscal fourth quarter and fiscal year ended January 31, 2025. "We are pleased with our solid finish to fiscal 2025 and I am excited about the new products we have introduced over the past several quarters that improve medication adherence and the overall patient and provider experience," said CEO and Co-Founder Chaim Indig. Please visit the Phr.

Positive
Zacks Investment Research
1 month ago
Phreesia (PHR) Moves 5.6% Higher: Will This Strength Last?
Phreesia (PHR) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.

Neutral
Business Wire
1 month ago
Phreesia's Sally Thayer Selected as a Top Woman Leader in Software
ALL-REMOTE COMPANY/WILMINGTON, Del.--(BUSINESS WIRE)--Phreesia announced that Sally Thayer, VP of Product Management, is a winner for The Software Report's 2024 list of Top 50 Women Leaders in Software.

Neutral
Business Wire
1 month ago
Phreesia Sets Release Date for Fiscal Fourth Quarter and Fiscal Year 2025 Results
ALL-REMOTE COMPANY/WILMINGTON, Del.--(BUSINESS WIRE)--Phreesia will release its fiscal fourth quarter and fiscal year 2025 financial results after the close of market trading on Wednesday, March 12.

Positive
Zacks Investment Research
2 months ago
Phreesia, Inc. (PHR) Soars to 52-Week High, Time to Cash Out?
Phreesia (PHR) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.

Neutral
Zacks Investment Research
2 months ago
Zacks Industry Outlook Enovis, Omnicell and Phreesia
Enovis, Omnicell and Phreesia have been highlighted in this Industry Outlook article.

Charts implemented using Lightweight Charts™